ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ODD ODDITY Tech Ltd.

Post-Mkt 08-18 17:10:37 EDT

12.30

+0.21

+1.74%

盘后12.30

+0.000.00%

16:47 EDT

High12.60	Low11.97	Vol835.71K
Open12.04	D1 Closing12.09	Amplitude5.21%
Mkt Cap567.33M	Tradable Cap351.61M	Total Shares46.12M
T/O10.32M	T/O Rate2.92%	Tradable Shares28.59M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ODD","market":"US","secType":"STK","nameCN":"ODDITY Tech Ltd.","latestPrice":12.3,"timestamp":1787083200000,"preClose":12.09,"halted":0,"volume":835705,"hourTrading":{"tag":"盘后","latestPrice":12.3,"preClose":12.3,"latestTime":"16:47 EDT","volume":20538,"amount":252619.20734400002,"timestamp":1787086048699,"change":0,"changeRate":0,"amplitude":0.014634},"delay":0,"changeRate":0.017369727047146472,"floatShares":28586000,"shares":46124600,"eps":0.79,"marketStatus":"Post-Mkt","change":0.21,"latestTime":"08-18 17:10:37 EDT","open":12.04,"high":12.6,"low":11.97,"amount":10321861.818514999,"amplitude":0.052109,"askPrice":14.11,"askSize":100,"bidPrice":10.98,"bidSize":100,"shortable":0,"etf":0,"ttmEps":0.79,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787097600000},"marketStatusCode":4,"adr":0,"listingDate":1689739200000,"exchange":"NASDAQ","adjPreClose":12.09,"preHourTrading":{"tag":"盘前","latestPrice":12.06,"preClose":12.09,"latestTime":"09:29 EDT","volume":862,"amount":10306.319394,"timestamp":1787059799999,"change":-0.03,"changeRate":-0.002481,"amplitude":0.038875},"postHourTrading":{"tag":"盘后","latestPrice":12.3,"preClose":12.3,"latestTime":"16:47 EDT","volume":20538,"amount":252619.20734400002,"timestamp":1787086048699,"change":0,"changeRate":0,"amplitude":0.014634},"volumeRatio":1.026522,"impliedVol":1.2932,"impliedVolPercentile":0.9801},"requestUrl":"/m/hq/s/ODD/wiki","defaultTab":"wiki","newsList":[{"id":"2657687386","title":"Press Release: Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657687386","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657687386?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:30","pubTimestamp":1786012200,"startTime":"0","endTime":"0","summary":"--  The Company advanced multiple global oncology and immunology programs. toward key clinical and regulatory milestones, with significant pipeline. --  Global Phase 1 data for zocilurtatug pelitecan  in combination. with a PD-L1 inhibitor in first-line SCLC to be presented at ESMO 2026;planned initiation of a registrational Phase 3 study later this year. --  Registrational Phase 3 DLLEVATE study evaluating zoci in second-line. plus SCLC remains on track, with enrollment expected to be completed in. the first half of 2027, supporting a potential U.S. accelerated approval. --  Global Phase 1/1b study of ZL-1503, a potential first-in-class. long-acting IL-13/IL-31R<ALPHA> bispecific antibody for the treatment of. atopic dermatitis, continues to advance, with initial first-in-human data. --  KarXT successfully launched in mainland China; encouraging early launch. trends building momentum ahead of potential NRDL inclusion. --  Total revenues of $106.3 million in the second quarter of 2026;","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4231","R","BK4232","BK4526","ODD","BK4531","LU2488822045.USD","BK4081","ADC","NETL","IND","BK4183","BK4548","BK4080","BK4585","IE0009354923.USD","ZLAB","BK4022","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657570414","title":"Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2657570414","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657570414?lang=en_us&edition=fundamental","pubTime":"2026-08-06 08:53","pubTimestamp":1785977580,"startTime":"0","endTime":"0","summary":"NANJING, China, Aug.  05, 2026  (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its Phase II clinical study evaluating ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3339882/0/en/Leads-Biolabs-Opamtistomig-PD-L1-4-1BB-Bispecific-Antibody-Advances-to-Expansion-Phase-in-First-Line-Hepatocellular-Carcinoma-Following-Positive-Efficacy-Signals.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTRN","COAL","BFAP","BTC","BITO","CBXY","BTF","PD","CBTY","OC","BETE","BRRR","YBTC","BPI","CBOO","BTCL","BFJL","BTFX","CBXA","BITB","BTCI","SBIT","ODD","CBOY","CBOJ","CBOA","BTCZ","HODL","BITX","CBTO","DFII","HCC","MNRS","CBXJ","BCCC","BTCC","CBTA","BTCO","BAGY","BETH","BTCW","XHB","BITY","CBXO","DEFI","BITI","EZBC","MAXI","GBTC","BITU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656554658","title":"Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2656554658","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656554658?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:15","pubTimestamp":1785849300,"startTime":"0","endTime":"0","summary":"LOS ANGELES, CA, Aug.  04, 2026  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced tha","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338423/0/en/Immix-Biopharma-to-Participate-in-the-Morgan-Stanley-24th-Annual-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","IE00B775SV38.USD","LU0128526141.USD","LU2487616109.SGD","LABU","LU1989772923.USD","LU1988902786.USD","LU0210528500.USD","LU1244550221.USD","HCSG","BK4585","LU2133065610.SGD","BK4588","LU0971096721.USD","LU1244550494.USD","LU2089283258.USD","LU1720051017.SGD","LU0528227936.USD","LU0795875169.SGD","LU1791710400.SGD","LU1548497426.USD","LU1074936037.SGD","LU2028103732.USD","BK4183","LU0320765646.SGD","LU1244550577.SGD","LU0234570918.USD","LU0882574139.USD","ODD","KBWB","XLV","LU0390134368.USD","BK4534","IE00BKVL7J92.USD","LU0106261372.USD","LU0267386448.USD","IE0009354923.USD","IAI","LU1668664300.SGD","LU1791710582.SGD","LU0314104364.USD","LU2023251221.USD","LU2347655156.SGD","LU0795875086.SGD","LU0098860793.USD","LU1732799900.SGD","XBI","BK4127","LU1720051108.HKD","LU1732800096.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656134744","title":"Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2656134744","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656134744?lang=en_us&edition=fundamental","pubTime":"2026-08-03 11:43","pubTimestamp":1785728580,"startTime":"0","endTime":"0","summary":"NANJING, China, Aug.  02, 2026  (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the Center for Drug Evaluation (CDE) of","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337201/0/en/Leads-Biolabs-PD-L1-4-1BB-Bispecific-Antibody-IND-Application-for-Combination-Therapy-in-Metastatic-Colorectal-Cancer-Approved-Further-Strengthening-Gastrointestinal-Oncology-Franc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTCO","CBXY","SIL","XBTY","MAXI","IDNA","BTCI","BITO","BITI","HCC","CBOJ","EZBC","FBTC","MNRS","COAL","BTCL","ODD","QBF","YBTC","BETH","BITX","MSS","BTRN","CRC","IND","CBXA","XHB","CDE","GDXJ","SGDM","CBTO","CBXJ","BCCC","CBTJ","BRRR","BITU","BTCZ","HODL","DEFI","ARKB","OC","BTC","CBOA","CBTA","CBXO","BFJL","PD","BITY","BTCW","XME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655368936","title":"Press Release: Radiopharm Theranostics Reports Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655368936","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655368936?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:00","pubTimestamp":1785495600,"startTime":"0","endTime":"0","summary":"endpoint, with 93% of patients treated with RAD 101 achieving concordance. with MRI imaging. Additionally, an interim analysis of 14 patients from. -- The Company anticipates the initiation of a Phase 3, multi-center,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","MEDX","HYLG","BK4139","GDOC","IDNA","IE0009354923.USD","ODD","RAD.AU","BK7067","BK4183","RADX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655180389","title":"ODDITY Tech Shareholders Approve All Proposals at 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2655180389","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655180389?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:55","pubTimestamp":1785444909,"startTime":"0","endTime":"0","summary":"ODDITY Tech Ltd. Class A ( ($ODD) ) has issued an announcement. On July 29, 2026, ODDITY Tech Ltd. held its Annual General Meeting of Shareholders ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oddity-tech-shareholders-approve-all-proposals-at-2026-annual-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oddity-tech-shareholders-approve-all-proposals-at-2026-annual-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","BK4183","ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655801671","title":"5 Microcap Software Stocks Expected to Soar by Triple Digits as the Companies' Sales Pop","url":"https://stock-news.laohu8.com/highlight/detail?id=2655801671","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655801671?lang=en_us&edition=fundamental","pubTime":"2026-07-30 23:48","pubTimestamp":1785426480,"startTime":"0","endTime":"0","summary":"These companies are all expected to show very rapid revenue growth through 2028These companies are all projected to increase revenue at a rapid pace through at least 2028. And analysts see very high u","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNTN","XPER","SVCO","BK4009","BLND","BK4096","BK4539","BK4603","ODD","RCAX","FTCI","BK4023","LIDR","BKSY","DSP","BK4123","IE0009354923.USD","BK4183","BK4187","BK4157","DRNZ","RCAT","WEAV","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653798736","title":"ODDITY to Announce Second Quarter 2026 Financial Results on September 9, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653798736","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653798736?lang=en_us&edition=fundamental","pubTime":"2026-07-23 04:05","pubTimestamp":1784750700,"startTime":"0","endTime":"0","summary":"NEW YORK, July  22, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced that it will release its second quarter 2026 financial results before the market open on Wednesday, Septembe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/22/3331716/0/en/ODDITY-to-Announce-Second-Quarter-2026-Financial-Results-on-September-9-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","IE0009354923.USD","ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653277765","title":"Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2653277765","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653277765?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:00","pubTimestamp":1784635200,"startTime":"0","endTime":"0","summary":"Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditionsCompany is exploring development, licensing, and co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/21/3330413/0/en/Cadrenal-Therapeutics-Launches-Partnering-Process-as-Its-Cardiac-Acute-Critical-Care-Assets-Advance-to-Transaction-Readiness-Following-Landmark-ISTH-Data-Presentation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4173","KD","LARK","BK4134","BK4183","HIT","IE0009354923.USD","IE0031619046.USD","BK4539","IE00B7SZL793.SGD","IE00B19Z4B17.USD","IE00B66KJ199.SGD","BK4139","BK4007","LENZ","ODD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648255544","title":"Oddity Tech CFO Lindsay Drucker Mann Disposes of USD 1.65 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2648255544","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648255544?lang=en_us&edition=fundamental","pubTime":"2026-07-01 23:22","pubTimestamp":1782919331,"startTime":"0","endTime":"0","summary":"Oddity Tech CFO Lindsay Drucker Mann disposes of USD 1.65 million in common sharesOddity Tech CFO Lindsay Drucker Mann sold 109,602 Class A ordinary shares on June 30, 2026 at about USD 15.09 and USD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL2zlsnf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oddity Tech CFO Lindsay Drucker Mann Disposes of USD 1.65 Million in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","ODD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647530232","title":"Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647530232","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647530232?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:05","pubTimestamp":1782817500,"startTime":"0","endTime":"0","summary":"-- Complete Response Letter relates to deficiencies previously identified at third-party manufacturing vendor -- -- FDA inspection of third-party facility did not occur during the NDA resubmission rev","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/30/3319541/0/en/Unicycive-Therapeutics-Receives-Complete-Response-Letter-from-FDA-Regarding-Resubmitted-Oxylanthanum-Carbonate-OLC-New-Drug-Application-NDA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0149725797.USD","LU2237443465.HKD","ODD","LU1363072403.SGD","LU2237443895.HKD","LU0029874061.USD","IE00BKVL7J92.USD","BK4121","LU0128526141.USD","BK4006","CMC","LABU","IE00BFXG1179.USD","LU0757428866.USD","BK4183","LU2237443978.SGD","LU0882574139.USD","LU2237443382.USD","BK4585","LU2237443622.USD","BK4139","LU0170899867.USD","IE00BHPRN162.USD","LU0267386448.USD","LU0971096721.USD","IE00B1BXHZ80.USD","LU1815336091.USD","LU0390134368.USD","IE00BZ1G4Q59.USD","IE0009354923.USD","BK4588","LU2746668461.USD","LU2237443549.SGD","BK4539","UNCY","CRL","LU2746668974.SGD","IE00BFMHRM44.USD","BK4530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645302473","title":"Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants","url":"https://stock-news.laohu8.com/highlight/detail?id=2645302473","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645302473?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:00","pubTimestamp":1782129600,"startTime":"0","endTime":"0","summary":"The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAVE Part A trial of elsunersen  Elsunersen demonstrated a 77% sham-adjusted reduction in monthly seizu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/22/3315249/0/en/Praxis-Precision-Medicines-Receives-FDA-Breakthrough-Therapy-Designation-for-Elsunersen-for-the-Treatment-of-Seizures-Associated-with-SCN2A-Developmental-and-Epileptic-Encephalopat.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE0009355771.USD","PRAX","BK4200","LU0109394709.USD","BK4139","ODD","IE0009354923.USD","IE00BFTCPJ56.SGD","LABU","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4183","BK4561","BK4585","IE0002141913.USD","IE00BJT1NW94.SGD","BK4588","BK4135","ASO","IE00B2B36J28.USD","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645021486","title":"Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645021486","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645021486?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:30","pubTimestamp":1782127800,"startTime":"0","endTime":"0","summary":"Company’s presentation will provide updates on SkinJect Phase 2b Pivotal Study in patients with Gorlin Syndrome and Teverelix Groundbreaking PRECISION-E2 Phase 2a Endometriosis Study leveraging the UA","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/22/3315195/0/en/Medicus-Pharma-to-Showcase-SkinJect-Registrational-Strategy-and-Teverelix-Precision-Medicine-Program-at-Bio-International-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","ODD","UAE","MDCX","BCC","BK4183","BK4567","BK4139","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644719516","title":"Oddity Tech board expands share buyback distribution up to $200 million under Israeli Companies Law","url":"https://stock-news.laohu8.com/highlight/detail?id=2644719516","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644719516?lang=en_us&edition=fundamental","pubTime":"2026-06-17 15:50","pubTimestamp":1781682623,"startTime":"0","endTime":"0","summary":"Oddity Tech’s board amended its share repurchase plan on June 15, 2026, enabling buybacks as a distribution under Israeli law.The plan authorizes up to $200 million of Class A ordinary share repurchases; $86,916,061 remained available as of the notice date.The board determined the remaining distribution meets the Companies Law solvency test, despite not satisfying the profit test.Repurchases may be executed in the open market or privately negotiated transactions, funded from existing cash, cash equivalents, and marketable securities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oddity Tech Ltd. published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL6LBg5d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ODD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644793704","title":"ODDITY Tech Sets July 29, 2026 AGM to Vote on Board, Auditor and Governance Matters","url":"https://stock-news.laohu8.com/highlight/detail?id=2644793704","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644793704?lang=en_us&edition=fundamental","pubTime":"2026-06-17 06:13","pubTimestamp":1781647983,"startTime":"0","endTime":"0","summary":"ODDITY Tech Ltd. Class A ( ($ODD) ) has shared an announcement. ODDITY Tech Ltd. has scheduled its Annual General Meeting of Shareholders for July ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oddity-tech-sets-july-29-2026-agm-to-vote-on-board-auditor-and-governance-matters?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oddity-tech-sets-july-29-2026-agm-to-vote-on-board-auditor-and-governance-matters?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","ODD","IE0009354923.USD","AGM","BK4229","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644576798","title":"Oddity Tech announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2644576798","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644576798?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:56","pubTimestamp":1781643392,"startTime":"0","endTime":"0","summary":"Oddity Tech will hold its annual general meeting in Tel Aviv-Jaffa on July 29, 2026.Shareholders will vote on reappointing Kost Forer Gabbay & Kasierer  as independent auditor for 2026.Director elections include Oran Holtzman as a Class III director through the 2029 annual meeting.Another vote covers re-electing Ohad Chereshniya as an external director for a new three-year term.Shareholders will also consider ratifying the employment terms of product manager Lihi Holtzman.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oddity Tech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL9S3zLZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","ODD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643205436","title":"Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643205436","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643205436?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:30","pubTimestamp":1781526600,"startTime":"0","endTime":"0","summary":"New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussionsAdditional billion-dollar target- Cardiac Surgery-Associated Ac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/15/3311786/0/en/Cadrenal-Therapeutics-Advances-Multi-Indication-Strategy-for-CAD-1005-Launches-Phase-2a-Acute-Kidney-Injury-CSA-AKI-Clinical-Plan-to-Accelerate-Pharma-Partnering-at-Upcoming-BIO-20.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4212","BK4585","AAQC","IE0009354923.USD","BIO","CPB","IE00BHPRN162.USD","ODD","BK4121","LENZ","BK4173","LU0149725797.USD","BK4139","BK4007","HIT","BK4539","BK4588","LU1169589451.USD","CSA","BK4183","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642983502","title":"Oddity Tech Unit to Repurchase $50 Million of Exchangeable Senior Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2642983502","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642983502?lang=en_us&edition=fundamental","pubTime":"2026-06-12 20:07","pubTimestamp":1781266053,"startTime":"0","endTime":"0","summary":"Oddity Tech  said Friday that its Oddity Finance unit has entered into privately negotiated repurchase agreements with holders of $50 million worth of 0% exchangeable senior notes due 2030.The consumer technology company said the repurchases are expected to close June 17 for a total purchase price of $35 million. After the repurchases close, the company said $550 million in worth of the existing notes will remain outstanding.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4183","ODD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642626062","title":"ODDITY Tech to Repurchase $50 Million of Exchangeable Notes at Discount","url":"https://stock-news.laohu8.com/highlight/detail?id=2642626062","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642626062?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:28","pubTimestamp":1781263732,"startTime":"0","endTime":"0","summary":"ODDITY Tech Ltd. Class A ( ($ODD) ) has provided an announcement. On June 11, 2026, Oddity Finance LLC, a wholly owned indirect subsidiary of ODDIT...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oddity-tech-to-repurchase-50-million-of-exchangeable-notes-at-discount?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oddity-tech-to-repurchase-50-million-of-exchangeable-notes-at-discount?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD","IE0009354923.USD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642973267","title":"Oddity Tech: Unit Entered Into Separate, Privately Negotiated Repurchase Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2642973267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642973267?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:11","pubTimestamp":1781262665,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nFWN42K09I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ODD","BK4183","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://oddity.com","stockEarnings":[{"period":"1week","weight":-0.0465},{"period":"1month","weight":-0.2594},{"period":"3month","weight":-0.0049},{"period":"6month","weight":-0.5967},{"period":"1year","weight":-0.7989},{"period":"ytd","weight":-0.6991}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0395},{"period":"3month","weight":0.0531},{"period":"6month","weight":0.1259},{"period":"1year","weight":0.2008},{"period":"ytd","weight":0.1331}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oddity Tech Ltd. operates as a consumer tech company that builds and scales digital-first brands to disrupt beauty and wellness industries. The company serves consumers worldwide through its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. It owns IL MAKIAGE and SpoiledChild brands. The company was incorporated in 2013 and is headquartered in Tel Aviv, Israel with additional office in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.053143},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.207461},{"month":3,"riseRate":0.666667,"avgChangeRate":0.025113},{"month":4,"riseRate":0.666667,"avgChangeRate":0.079804},{"month":5,"riseRate":0.666667,"avgChangeRate":0.086142},{"month":6,"riseRate":1,"avgChangeRate":0.075724},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.034719},{"month":8,"riseRate":0,"avgChangeRate":-0.149446},{"month":9,"riseRate":0.666667,"avgChangeRate":-0.062117},{"month":10,"riseRate":0,"avgChangeRate":-0.140574},{"month":11,"riseRate":0.666667,"avgChangeRate":0.166696},{"month":12,"riseRate":0.333333,"avgChangeRate":0.066185}],"exchange":"NASDAQ","name":"ODDITY Tech Ltd.","nameEN":"ODDITY Tech Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ODDITY Tech Ltd.(ODD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ODDITY Tech Ltd.,ODD,ODDITY Tech Ltd.股票,ODDITY Tech Ltd.股票老虎,ODDITY Tech Ltd.股票老虎国际,ODDITY Tech Ltd.行情,ODDITY Tech Ltd.股票行情,ODDITY Tech Ltd.股价,ODDITY Tech Ltd.股市,ODDITY Tech Ltd.股票价格,ODDITY Tech Ltd.股票交易,ODDITY Tech Ltd.股票购买,ODDITY Tech Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ODDITY Tech Ltd.(ODD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}